What is Impact BioMedical's market cap?

Impact BioMedical (IBO) has a market capitalization of $46.6M and trades on XASE.

Who are Impact BioMedical's competitors?

Impact BioMedical's key competitors include Pfizer Inc., Johnson & Johnson, PMGC Holdings Inc. Common Stock, and others. These companies compete in similar markets and product categories.

Who does Impact BioMedical partner with?

Impact BioMedical's notable partners include ProPhase Laboratories, Chemia Corporation, Dr. Ashleys Limited, and others.

What subsidiaries does Impact BioMedical have?

Impact BioMedical's subsidiaries include Global BioLife, Inc., Impact BioLife Science, Inc., Global BioMedical, Inc., and others.

Where is Impact BioMedical headquartered?

Impact BioMedical is headquartered in United States of America and employs approximately 5 people. It has been publicly traded since 2024.

Impact BioMedical

IBO

Impact BioMedical is a biotechnology company focused on the discovery, patenting, and development of proprietary science and technologies for human healthcare and wellness.

Market cap

$46.58M-30.9%

Table of contents

Earnings

Q1 2026 report

May 12, 2026

Revenue$7.0K EPS-$0.02

Read the full report

Next report

Date not yet announced

Competitors

By market cap

Johnson & Johnson$640.91B+60.1%

Pfizer$140.61B+1.7%

Ginkgo Bioworks$486.7M-40.4%

Impact BioMedical$46.6M-34.6%

HIN

Vyome Holdings, Inc.$14.0M—

Exicure$11.2M-75.5%

Bolt Biotherapeutics, Inc.$7.6M-36.8%

ELA

Elevai Labs, Inc.$4.2M+33.9%

By revenue growth

Johnson & Johnson+8.1%

Pfizer+1.4%

Ginkgo Bioworks-37.8%

By net margin

Johnson & Johnson21.48%-3.5pp

Pfizer15.65%+6.3pp

Ginkgo Bioworks-215.41%-7.7pp

Profile

Impact BioMedical is a biotechnology company focused on the discovery, patenting, and development of proprietary science and technologies for human healthcare and wellness. The company leverages a robust intellectual property portfolio to address unmet needs in oncology, neurology, and inflammatory diseases through a collaborative model of licensing and co-development.

Competitive position

Impact BioMedical acts as an innovation incubator that secures early-stage IP and seeks to monetize it through strategic partnerships with established commercial entities.

GeographiesUnited States, Europe, Global

Customer segmentsEnterprise, Consumer Healthcare

Business modelIP Licensing, Research and Development, Royalty-based

SuppliersAcademic research institutions, Specialty chemical suppliers, Patent attorneys and regulatory consultants

CustomersGlobal pharmaceutical firms, CPG manufacturers, Retail distribution networks

CountryUnited States of America

Listed2024

Employees5.0

CEOFrank D. Heuszel

SectorHealthcare

IndustryBiotechnology

Websiteimpactbiomedinc.com

FilingsSEC EDGAR

Questions, answered.

What is Impact BioMedical's market cap?: Impact BioMedical (IBO) has a market capitalization of $46.6M and trades on XASE.
Who are Impact BioMedical's competitors?: Impact BioMedical's key competitors include Pfizer Inc., Johnson & Johnson, PMGC Holdings Inc. Common Stock, and others. These companies compete in similar markets and product categories.
Who does Impact BioMedical partner with?: Impact BioMedical's notable partners include ProPhase Laboratories, Chemia Corporation, Dr. Ashleys Limited, and others.
What subsidiaries does Impact BioMedical have?: Impact BioMedical's subsidiaries include Global BioLife, Inc., Impact BioLife Science, Inc., Global BioMedical, Inc., and others.
Where is Impact BioMedical headquartered?: Impact BioMedical is headquartered in United States of America and employs approximately 5 people. It has been publicly traded since 2024.